Literature DB >> 22534284

Targeted radio-nuclide therapy of skeletal metastases.

Oliver Sartor1, Peter Hoskin, Oyvind S Bruland.   

Abstract

In this review, we will focus on one particular class of stromal targeted therapy, i.e. the bone seeking radiopharmaceuticals (BSRs), but will also highlight selected issues related to the bone stroma as these concepts are new, rapidly evolving, and clearly linked to the underlying BSR mechanisms of targeting and action. Herein we review clinical BSR-trials of significance with randomized trials at center stage. Furthermore, we cover a new class of BSR in late clinical development based on bone-stromal targeted alpha-particle irradiation. Lastly, we discuss potential advances in combining BSR with bisphosphonates and/or chemotherapy and emphasize the feasibility of repeated dosing.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22534284     DOI: 10.1016/j.ctrv.2012.03.006

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  10 in total

Review 1.  Targeted α-particle therapy of bone metastases in prostate cancer.

Authors:  Hossein Jadvar; David I Quinn
Journal:  Clin Nucl Med       Date:  2013-12       Impact factor: 7.794

2.  Radionuclide calibrator responses for 224Ra in solution and adsorbed on calcium carbonate microparticles.

Authors:  Elisa Napoli; Jeffrey T Cessna; Leticia Pibida; Ryan Fitzgerald; Gro E Hjellum; Denis E Bergeron
Journal:  Appl Radiat Isot       Date:  2020-06-12       Impact factor: 1.513

Review 3.  Usefulness of radium-223 in patients with bone metastases.

Authors:  Nishant Gupta; Arushi Devgan; Itisha Bansal; Thomas D Olsavsky; Shuo Li; Ahmed Abdelbaki; Yogesh Kumar
Journal:  Proc (Bayl Univ Med Cent)       Date:  2017-10

4.  The study of external dose rate and retained body activity of patients receiving 131I therapy for differentiated thyroid carcinoma.

Authors:  Haiying Zhang; Ling Jiao; Songye Cui; Liang Wang; Jian Tan; Guizhi Zhang; Yajing He; Shuzhou Ruan; Saijun Fan; Wenyi Zhang
Journal:  Int J Environ Res Public Health       Date:  2014-10-21       Impact factor: 3.390

5.  Real-time scintigraphic assessment of intravenous radium-223 administration for quality control.

Authors:  Chadwick L Wright; J Paul Monk; Douglas A Murrey; Nathan C Hall
Journal:  Biomed Res Int       Date:  2015-02-18       Impact factor: 3.411

6.  (177)Lu-labelled macrocyclic bisphosphonates for targeting bone metastasis in cancer treatment.

Authors:  Ralf Bergmann; Marian Meckel; Vojtěch Kubíček; Jens Pietzsch; Jörg Steinbach; Petr Hermann; Frank Rösch
Journal:  EJNMMI Res       Date:  2016-01-16       Impact factor: 3.138

Review 7.  Radium-223 Therapy for Patients with Metastatic Castrate-Resistant Prostate Cancer: An Update on Literature with Case Presentation.

Authors:  Nghi C Nguyen; Muhammad Shah; Leonard J Appleman; Rahul Parikh; James M Mountz
Journal:  Int J Mol Imaging       Date:  2016-09-27

Review 8.  Novel Radiolabeled Bisphosphonates for PET Diagnosis and Endoradiotherapy of Bone Metastases.

Authors:  Nina Pfannkuchen; Marian Meckel; Ralf Bergmann; Michael Bachmann; Chandrasekhar Bal; Mike Sathekge; Wolfgang Mohnike; Richard P Baum; Frank Rösch
Journal:  Pharmaceuticals (Basel)       Date:  2017-05-18

Review 9.  Biological and Clinical Aspects of Metastatic Spinal Tumors.

Authors:  Jakub Litak; Wojciech Czyżewski; Michał Szymoniuk; Leon Sakwa; Barbara Pasierb; Joanna Litak; Zofia Hoffman; Piotr Kamieniak; Jacek Roliński
Journal:  Cancers (Basel)       Date:  2022-09-22       Impact factor: 6.575

10.  Ra-224 labeling of calcium carbonate microparticles for internal α-therapy: Preparation, stability, and biodistribution in mice.

Authors:  Sara Westrøm; Marion Malenge; Ida Sofie Jorstad; Elisa Napoli; Øyvind S Bruland; Tina B Bønsdorff; Roy H Larsen
Journal:  J Labelled Comp Radiopharm       Date:  2018-03-12       Impact factor: 1.921

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.